http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
호알칼리성 Bacillus sp. No. 4의 Cyclodextrin Glycosyltransferase에 의한 Glycosyl Sucrose의 생산과 저충치성 당으로서의 응용
손천배,유미경,김명희,문숙경 충남대학교부설 생명공학연구소 1992 생물공학연구지 Vol.2 No.-
Action of a cyclodextrin glycosyltransferase (CGTase) produce from alkalophilic Bacillus sp. No. 4 was studied in a solution containing starch and sucrose to prepare glycosyl sucrose syrup with good sweetness and antidecaying properties of teeth. In the initial stage of the reaction the CGTase produced cyclodextrin, however, the cyclodextrin disappeared and glycosyl sucrose was formed with the lapse of reaction time. The best proportion of sucrose to starch for prodution of glycosyl sucrose was about 1 : 1. The optimum pH and temperature of the coupling reaction was pH 6.0 and 60℃, respectively. Main composition of glycosyl sucrose syrup prepared with 20% starch and 20% sucrose was sucrose 18%, glucosyl sucrose (G_2F) 15.3% and amltosyl sucorse (G_3F) 11.3%. And glucose, maltose and maltotriose were produced very little. Smaller amounts of acid and insoluble glucan were formed in the syrup by Streptococcus mtans OMZ176 than in the sucrose. Therefore, the prepared glycosyl sucrose sucrose syrup is expected to prevent teeth from decaying.
박용관,김태원,장영,김진호,강정원,천영욱,박유환,정춘해 조선대학교 1995 The Medical Journal of Chosun University Vol.20 No.1
Multiple myeloma is a disease caused by neoplastic plasma cells that synthesize abnormal amouts of immunoglobulin or immunoglobulin fragments. Light chain myeloma are regarded as a separate category characterized by a more malignant clinical course. Light chain myelomas are said to grow fastest of all and are associated with more osteolytic lesions, more hypercalcemia, and a higher incidence of renal failure and amyloidsis than either the IgG, IgA varienties The authors experienced a case of patients with λ-light chain myeloma. A 43-year-old male patient admitted to our hospital with the chief complaint of both rib and lower back pain. The radiologic findings showed multiple pathologic fracture in ribs. osteolytic lesions in 2nd, 3rd cervical spineimmuture plasma cells. Serum electrophoresis showed normal finding. Urine electrophoresis evealed an M-spike. Urine immunoelectrophoress demonstrated λ-monoclonal protein. With the cycle of melphalan, prednisone and α-interferon chemotherapy improved of pain was observed. So we reported the case with brief review of previous literature.
조은택,박용관,김진호,강정원,천영욱,전익섭,박유환,전춘해 조선대학교 1995 The Medical Journal of Chosun University Vol.20 No.1
Malignant histiocytosis, originally described in 1939 as histiocytic medullary reticulosis by Scott and Robb-Smith, is a rare histiocytic proliferative disorder that often shows an acute onset and used to progress to death within a few months. This disorder characterized clinically by fever, generalized weakness, lymphadenopathy and hepatosplenomegaly, and shows a variable range of pancytopenia. Extranodal involvement is common, with an incidence ranging from 50% to as high as 90%, skin involves8ment was noted in 10% to 15%. Typical skin lesions were mainly founded in extremity. i.e. erythematous papule and nodule occasionally become to necrosis and ulceration. We experienced one case of malignant histiocytosis in a 46-years-old female. The major clinical findings are fever, malaise, hepatosplenomegaly and erythematous skin lesion. In the laboratory study, pancytopenia is noted on the peripheral blood. And also aggregation of many atypical histiocytes were shown on skin and bone marrow biopsy. So we reported one related case with malignant histiocytosis as well as reviewing literature .
A Case Report of Herpes Zoster Ophthalmicus and Meningitis After COVID-19 Vaccination
You In-Cheon,Ahn Min,Cho Nam-Chun 대한의학회 2022 Journal of Korean medical science Vol.37 No.20
There are several reports that herpes zoster characterized by reactivation of varicella zoster virus (VZV) following coronavirus disease 2019 (COVID-19) vaccines can occur. Herein, we report VZV meningitis, herpes zoster ophthalmicus (HZO), and late neurotrophic keratitis after receiving a second dose of messenger RNA (mRNA) COVID-19 vaccine. A 74-year-old man developed a vesicular skin rash on the forehead, scalp, nose, and left upper eyelid with a severe headache. Five days earlier, he received a second dose of the BNT162b2 mRNA vaccine on his left arm. Ocular examination revealed conjunctival hyperemia and pseudodendrite in the peripheral cornea. VZV was detected in the cerebrospinal fluid using polymerase chain reaction. The patient was diagnosed with HZO and meningitis. The patient was treated with intravenous acyclovir and topical acyclovir ointment and levofloxacin 1.5% eye drops. One month later, he developed a central epithelial defect with a rolled margin, typical of a neurotrophic ulcer. Treatment with a therapeutic contact lens and a combination of topical recombinant human epithelial growth factor and ofloxacin ointment was initiated. At six months after vaccination, the slit-lamp examination findings were stable with a mild corneal superficial stromal haze.
You, In-Cheon,Kang, In-Seong,Lee, Seung-Hyun,Yoon, Kyung-Chul Blackwell Publishing Ltd 2009 Acta ophthalmologica Vol.87 No.6
<P>Abstract.</P><P>Purpose: </P><P>To investigate the efficacy of subconjunctival injection of bevacizumab in the treatment of patients with corneal neovascularization.</P><P>Methods: </P><P>Twenty-nine eyes of 29 patients with corneal neovascularization were treated with subconjunctival injection [1.25 mg/0.05 ml (seven eyes), 2.5 mg/0.1 ml (15 eyes) and 5.0 mg/0.2 ml (seven eyes)] of bevacizumab. Best-corrected visual acuity, intraocular pressure and area of corneal neovascularization were measured before injection and at 1 week, 1 month and 3 months after treatment.</P><P>Results: </P><P>At 1 week, the mean neovascularized corneal area decreased significantly to 85.5 ± 18.0% (<I>p</I> =<I> </I>0.01) in the eyes treated with 2.5 mg bevacizumab and to 73.1 ± 23.4% (<I>p</I> =<I> </I>0.02) in the eyes treated with 5.0 mg bevacizumab. At 3 months, the mean neovascularized corneal area was 93.6 ± 10.6% (<I>p</I> =<I> </I>0.10 compared to baseline; <I>p</I> <<I> </I>0.01 compared to 1 week) in the eyes treated with 2.5 mg bevacizumab and 83.3 ± 25.8% (<I>p</I> =<I> </I>0.03 compared to baseline; <I>p</I> =<I> </I>0.02 compared to 1 week) in the eyes treated with 5.0 mg bevacizumab. However, there were no significant changes in the areas of the eyes injected with 1.25 mg bevacizumab.</P><P>Conclusion: </P><P>Subconjunctival injection of bevacizumab can partially reduce corneal neovascularization in the short term, and the efficacy of this treatment correlates with the injection dose.</P>